Using the adgrl3.1 zebrafish mutant model of ADHD [7], we previously identified five compounds with the potential to be repurposed for ADHD treatment: aceclofenac, amlodipine, doxazosin, moxonidine, and LNP599 [7]. Here, ADGRL3 is linked to attention deficit-hyperactivity disorder.